Replies to post #80051 on Amarantus Bioscience Holdings Inc (AMBS)

[dshade]

Key points. AMBS's patents were upheld in court:


(7) It has been shown that MANF performs better than CDNF and GDNF in pre clinical trials.

(8) GDNF was owned by a company purchased for $250 Million during pre-clinical trials.

[blackhawks]

Amarantus will pump into Hermo Pharma at the European Neurotech Investing and Partnering Summit 2013 in September

Great!

Chelby, how about a 'crystal ball consult' for the impact on AMBS pps around 6 hours after Gerald speaks on Wednesday September 4, 2013. (Helsinki Time 10:30 AM....New York Time 3:30 AM)

You can of course update your prediction if you believe that Gerald will board the plane to Helsinki with a glowing LymPro AD blood test assay result AND a committment of financial support from BD, OR news of a bidding war over Lympro between Lilly and or Pfizer and BD, in his briefcase, all to be announced live to the conference audience and simultaneously PR'd in the US.

[joboggi]

Neurturin and GDNF did get funded. The ? is, do you think that they failed or not. If you do think they failed, then it is much less likely that MANF will get funded.

OTOH, IF MANF is studied in humans, it will take over $100 million to study it.